Abstract
The probability of survival is conventionally calculated from autologous hematopoietic cell transplantation (aHCT). Conditional survival takes into account the changing probability of survival with time survived, but this is not known for aHCT populations. We determined disease- and cause-specific conditional survival for 2388 patients treated with aHCT over a period of 20 years at a single institution. A total of 1054 deaths (44% of the cohort) were observed: 78% attributed to recurrent disease; 9% to subsequent malignancies and 6% to cardiopulmonary disease. Estimated probability of relative survival was 62% at 5 years and 50% at 10 years from aHCT. On the other hand, the 5-year relative survival was 70, 75, 81 and 88% after having survived 1, 2, 5 and 10 years after aHCT, respectively. The cohort was at a 13.9-fold increased risk of death compared with the general population (95% confidence interval (CI)=13.1–14.8). The risk of death approached that of the general population for 10-year survivors (standardized mortality ratio (SMR)=1.4, 95% CI=0.9–1.9), with the exception of female Hodgkin’s lymphoma patients transplanted before 1995 at age ⩽40 years (SMR=6.0, 95% CI=1.9–14.0). Among those who had survived 10 years, nonrelapse-related mortality rates exceeded relapse-related mortality rates. This study provides clinically relevant survival estimates after aHCT, and helps inform interventional strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Appelbaum F, Herzig G, Ziegler J, Graw R, Levine A, Deisseroth A . Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978; 52: 85–95.
Horowitz M (ed) Uses and Growth of Hematopoietic Cell Transplantation. Blackwell: Malden, MA, 2004.
Bhatia S, Robison LL, Francisco L, Carter A, Liu Y, Grant M et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105: 4215–4222.
Henson D, Ries L, Carriaga M . Conditional survival of 56,268 patients with breast cancer. Cancer 1995; 76: 237–242.
Merrill R, Henson D, Ries L . Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. Dis Colon Rectum 1998; 41: 1097–1106.
Skuladottir H, Olsen J . Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol 2003; 21: 3035–3040.
Wang S, Emery R, Fuller D, Kim J, Sittig D, Thomas C . Conditional survival of gastric cancer: a SEER database analysis. Gastric Cancer 2007; 10: 153–158.
Janssen-Heijnen ML, van Steenbergen LN, Steyerberg E, Visser O, De Ruysscher DK, Groen HJ . Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands. J Thorac Oncol 2012; 7: 496–502.
Bouvier AM, Remontet L, Hedelin G, Launoy G, Jooste V, Grosclaude P et al. Conditional relative survival of cancer patients and conditional probability of death: a French National Database analysis. Cancer 2009; 115: 4616–4624.
Marsh G, Ehland J, Sefcik S, Youk A . Mortality and Population Data System. University of Pittsburgh: Pittsburgh, PA, 2000.
Breslow N, Day N . Fitting Models to Grouped Data. Statistical Methods in Cancer Research Vol 2. International Agency for Research on Cancer. IARC Scientific Publications, No. 82: Lyon, France, 1987.
Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimates. Stat Med 1999; 18: 695–706.
Nivison-Smith I, Simpson JM, Dodds AJ, Ma DDF, Szer J, Bradstock KF . Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Biol Blood Marrow Transplant 2009; 15: 1323–1330.
Gorin NC, Labopin M, Meloni G, Korbling M, Carella A, Herve P et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). Leukemia 1991; 5: 896–904.
Sun CL, Francisco L, Kawashima T, Leisenring W, Robison LL, Baker KS et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010; 116: 3129–3139.
Hill BT, Rybicki L, Bolwell BJ, Smith S, Dean R, Kalaycio M et al. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Br J Haematol 2011; 152: 561–569.
Jantunen E, Itala M, Siitonen T, Koivunen E, Leppa S, Juvonen E et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Eur J Haematol 2006; 77: 114–119.
Oddou S, Vey N, Viens P, Bardou VJ, Faucher C, Stoppa AM et al. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma 1998; 31: 187–194.
Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588–1593.
Armenian SH, Sun CL, Francisco L, Steinberger J, Kurian S, Wong FL et al. Late congestive heart failure after hematopoietic cell transplantation. J Clin Oncol 2008; 26: 5537–5543.
Villani F, De Maria P, Bonfante V, Viviani S, Laffranchi A, Dell’oca I et al. Late pulmonary toxicity after treatment for Hodgkin’s disease. Anticancer Res 1997; 17: 4739–4742.
Kalaycio M, Pohlman B, Kuczkowski E, Rybicki L, Andresen S, Sobecks R et al. High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant. Clin Transplant 2006; 20: 783–787.
Chen CI, Abraham R, Tsang R, Crump M, Keating A, Stewart AK . Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant 2001; 27: 177–182.
Jules-Elysee K, Stover DE, Yahalom J, White DA, Gulati SC . Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation. Am Rev Respir Dis 1992; 146: 485–491.
Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ et al. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol 2010; 17: 2015–2023.
Moller MB, Pedersen NT, Christensen BE . Conditional survival of patients with diffuse large B-cell lymphoma. Cancer 2006; 106: 2165–2170.
Ellison LF, Bryant H, Lockwood G, Shack L . Conditional survival analyses across cancer sites. Health Rep 2011; 22: 21–25.
Baade PD, Youlden DR, Chambers SK . When do I know I am cured? Using conditional estimates to provide better information about cancer survival prospects. Med J Aust 2011; 194: 73–77.
Janssen-Heijnen ML, Gondos A, Bray F, Hakulinen T, Brewster DH, Brenner H et al. Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol 2010; 28: 2520–2528.
Merrill RM, Hunter BD . Conditional survival among cancer patients in the United States. Oncologist 2010; 15: 873–882.
Sant M, Allemani C, Santaguiklani M, Knijn A, Marchesi F, Capocaccia R et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931–991.
Chang GJ, Hu CY, Eng C, Skibber JM, Rodriguez-Bigas MA . Practical application of a calculator for conditional survival in colon cancer. J Clin Oncol 2009; 27: 5938–5943.
Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010; 116: 2234–2241.
Meng L, Maskarinec G, Lee J . Ethnicity and conditional breast cancer survival in Hawaii. J Clin Epidemiol 1997; 50: 1289–1296.
Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230–2239.
Martin PJ, Counts GW, Appelbaum FR, Lee SJ, Sanders JE, Deeg J et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol 2010; 28: 1011–1016.
Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol 2010; 28: 1888–1895.
Majhail NS, Bajorunaite R, Lazarus HM, Wang Z, Klein JP, Zhang MJ et al. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. Br J Haematol 2009; 147: 129–139.
Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784–3792.
Acknowledgements
This study was supported in part by grants from the National Institute of Health (R01 CA078938 (to SB), P01 CA 30206 (to SJF) and the Leukemia Lymphoma Society (2192 (to SB)).
Author contributions
Ari M VanderWalde performed the research, analyzed and interpreted the data and wrote the manuscript. Can-Lan Sun analyzed and interpreted the data and wrote the manuscript. Lester Laddaran and Liton Francisco performed the research and interpreted the data. Saro Armenian, F Lennie Wong, Leslie Popplewell, George Somlo, Anthony S Stein, Auayporn Nademanee, Amrita Krishnan, Neil Kogut, Stephen J Forman provided critical insight in the interpretation of the data. Jennifer Berano-Teh performed the research and interpreted the data. Smita Bhatia procured funding, designed the study, supervised and performed the research, analyzed and interpreted the data and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
VanderWalde, A., Sun, CL., Laddaran, L. et al. Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. Leukemia 27, 1139–1145 (2013). https://doi.org/10.1038/leu.2012.311
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.311
Keywords
This article is cited by
-
Conditional survival in multiple myeloma and impact of prognostic factors over time
Blood Cancer Journal (2023)
-
Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation
Bone Marrow Transplantation (2021)
-
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
British Journal of Cancer (2016)
-
A randomized clinical trial on the effectiveness of an intervention to treat psychological distress and improve quality of life after autologous stem cell transplantation
Annals of Hematology (2016)